Patents by Inventor Patrick Michael Andrae

Patrick Michael Andrae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 8063053
    Abstract: The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: November 22, 2011
    Assignee: Wyeth LLC
    Inventors: Simon Nicolas Haydar, Patrick Michael Andrae, Heedong Yun, Albert Jean Robichaud
  • Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation
    Publication number: 20100168106
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles
    Type: Application
    Filed: March 8, 2010
    Publication date: July 1, 2010
    Applicant: Wyeth LLC
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20100120779
    Abstract: The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: November 11, 2009
    Publication date: May 13, 2010
    Applicant: Wyeth
    Inventors: Simon Nicolas Haydar, Patrick Michael Andrae, Heedong Yun, Albert Jean Robichaud
  • Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for ?-secretase modulation
    Patent number: 7705030
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: April 27, 2010
    Assignee: Wyeth LLC
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • 3-aryl-4-hydroxyfuranone compounds and the human and animal health use thereof
    Patent number: 7666904
    Abstract: The present invention provides a compound of formula I and the use thereof for the inhibition of bacterial cell wall biosynthesis and for the therapeutic treatment of bacterial infection or disease in a patient in need thereof. The present invention also provides the use of the formula I compound for the control of ecto- or endoparasites in homeothermic animals.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: February 23, 2010
    Assignee: Wyeth LLC
    Inventors: Craig Eugene Caufield, Schuyler Adam Antane, Koi Michele Morris, Shaughnessy McGrath Naughton, Dominick Anthony Quagliato, Patrick Michael Andrae, Annmarie Enos, John F. Chiarello
  • Dihydrospiro[dibenzo[a,d][7]annulene-5,4?-imidazol] compounds for the inhibition of beta-secretase
    Patent number: 7582667
    Abstract: The present invention provides a 10,11-dihydrospiro[dibenzo[a,d][7]annulene -5,4?-imidazol]-5?(1?H)-one compound of formula I Also provided are methods and compositions for the inhibition of ?-secretase (BACE) and the treatment of ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Dominick Anthony Quagliato, Patrick Michael Andrae, Yi Fan
  • 3-aryl-4-hydroxyfuranone compounds and the human and animal health use thereof
    Patent number: 7495027
    Abstract: The present invention provides a compound of formula I and the use thereof for the inhibition of bacterial cell wall biosynthesis and for the therapeutic treatment of bacterial infection or disease in a patient in need thereof.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: February 24, 2009
    Assignee: Wyeth
    Inventors: Craig Eugene Caufield, Schuyler Adam Antane, Koi Michele Morris, Shaughnessy McGrath Naughton, Dominick Anthony Quagliato, Patrick Michael Andrae, Annmarie Enos, John F. Chiarello
  • 3-ARYL-4-HYDROXYFURANONE COMPOUNDS AND THE HUMAN AND ANIMAL HEALTH USE THEREOF
    Publication number: 20090036439
    Abstract: The present invention provides a compound of formula I and the use thereof for the inhibition of bacterial cell wall biosynthesis and for the therapeutic treatment of bacterial infection or disease in a patient in need thereof. The present invention also provides the use of the formula I compound for the control of ecto- or endoparasites in homeothermic animals.
    Type: Application
    Filed: September 19, 2008
    Publication date: February 5, 2009
    Applicant: Wyeth
    Inventors: Craig Eugene Caufield, Schuyler Adam Antane, Koi Michele Morris, Shaughnessy McGrath Naughton, Dominick Anthony Quagliato, Patrick Michael Andrae, Annmarie Enos, John F. Chiarello
  • AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION
    Publication number: 20080306091
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles
    Type: Application
    Filed: July 28, 2008
    Publication date: December 11, 2008
    Applicant: Wyeth
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for ?-secretase modulation
    Patent number: 7417047
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 26, 2008
    Assignee: Wyeth
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase
    Publication number: 20070203116
    Abstract: The present invention provides a 10,11-dihydrospiro[dibenzo[a,d][7]annulene-5,4?-imidazol]-5?(1?H)-one compound of formula I Also provided are methods and compositions for the inhibition of ?-secretase (BACE) and the treatment of ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: February 23, 2007
    Publication date: August 30, 2007
    Applicant: Wyeth
    Inventors: Dominick Anthony Quagliato, Patrick Michael Andrae, Yi Fan
  • Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
    Patent number: 6458817
    Abstract: This invention provides compounds of Formula I having the structure wherein R1, R2, R3, R4, R5, R6, Y, Z, m, n, and are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: October 1, 2002
    Assignee: Wyeth
    Inventors: Dominick Anthony Quagliato, Patrick Michael Andrae